SOURCE: Healthnostics, Inc.

November 15, 2010 08:44 ET

Healthnostics Implements 3-S Program With One-Machine-One-Product Concept

Company Adding Three New Machines

NEW YORK, NY--(Marketwire - November 15, 2010) - Healthnostics, Inc. (PINKSHEETS: HNSS) is implementing its 3-S Program of "speed, space, and specialization" by unveiling its One-Machine-One-Product concept and announced the building of three new medical product manufacturing machines based upon the same technology as its fill-and-seal MicroFill-2160 machine announced in October. When completed, the three machines along with MicroFill-2160 will take up less space and operate nearly 12 times faster than a much larger traditional machine using the same number of employees and occupying the same amount of floor space.

Due to their speed, size, and low labor intensity, each machine will be allocated a different product. This One-Machine-One-Product concept will increase efficiency and profitability by (a) requiring no changeable parts other than print plates, (b) requiring no down time for product changeovers, (c) increasing productivity through labor specialization, (d) reducing losses caused by shutdown and startup waste, and (e) eliminating production line interruptions caused by packaging changes.

About Healthnostics

Healthnostics, Inc. is a medical product manufacturer, system manufacturer and product distributor company. Healthnostics' subsidiary, Worldwide Wipes Co., is a manufacturer and distributor of medical and general swabs.

For further information please visit Healthnostics, and Worldwide Wipes Co.

And visit us on Facebook at

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

Contact Information

  • Contact:
    Healthnostics, Inc.
    Investor Relations
    P. 301-956-3342
    Email Contact